296 related articles for article (PubMed ID: 30223181)
1. The gut-liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19.
Piglionica M; Cariello M; Moschetta A
Curr Opin Pharmacol; 2018 Dec; 43():93-98. PubMed ID: 30223181
[TBL] [Abstract][Full Text] [Related]
2. The Enterokine Fibroblast Growth Factor 15/19 in Bile Acid Metabolism.
Cariello M; Piglionica M; Gadaleta RM; Moschetta A
Handb Exp Pharmacol; 2019; 256():73-93. PubMed ID: 31123830
[TBL] [Abstract][Full Text] [Related]
3. Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis.
Gadaleta RM; Scialpi N; Peres C; Cariello M; Ko B; Luo J; Porru E; Roda A; Sabbà C; Moschetta A
Sci Rep; 2018 Nov; 8(1):17210. PubMed ID: 30464200
[TBL] [Abstract][Full Text] [Related]
4. Nuclear receptor FXR, bile acids and liver damage: Introducing the progressive familial intrahepatic cholestasis with FXR mutations.
Cariello M; Piccinin E; Garcia-Irigoyen O; Sabbà C; Moschetta A
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1308-1318. PubMed ID: 28965883
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling.
Di Ciaula A; Bonfrate L; Baj J; Khalil M; Garruti G; Stellaard F; Wang HH; Wang DQ; Portincasa P
Nutrients; 2022 Nov; 14(23):. PubMed ID: 36500979
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor.
Gadaleta RM; Garcia-Irigoyen O; Cariello M; Scialpi N; Peres C; Vetrano S; Fiorino G; Danese S; Ko B; Luo J; Porru E; Roda A; Sabbà C; Moschetta A
EBioMedicine; 2020 Apr; 54():102719. PubMed ID: 32259714
[TBL] [Abstract][Full Text] [Related]
7. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis.
Modica S; Petruzzelli M; Bellafante E; Murzilli S; Salvatore L; Celli N; Di Tullio G; Palasciano G; Moustafa T; Halilbasic E; Trauner M; Moschetta A
Gastroenterology; 2012 Feb; 142(2):355-65.e1-4. PubMed ID: 22057115
[TBL] [Abstract][Full Text] [Related]
8. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.
Hernandez GV; Smith VA; Melnyk M; Burd MA; Sprayberry KA; Edwards MS; Peterson DG; Bennet DC; Fanter RK; Columbus DA; Steibel JP; Glanz H; Immoos C; Rice MS; Santiago-Rodriguez TM; Blank J; VanderKelen JJ; Kitts CL; Piccolo BD; La Frano MR; Burrin DG; Maj M; Manjarin R
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G582-G609. PubMed ID: 32003601
[TBL] [Abstract][Full Text] [Related]
9. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
Mellor HR
Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
[TBL] [Abstract][Full Text] [Related]
10. Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis.
Byun S; Kim DH; Ryerson D; Kim YC; Sun H; Kong B; Yau P; Guo G; Xu HE; Kemper B; Kemper JK
Nat Commun; 2018 Jul; 9(1):2590. PubMed ID: 29968724
[TBL] [Abstract][Full Text] [Related]
11. Impaired Intestinal Farnesoid X Receptor Signaling in Cystic Fibrosis Mice.
Ikpa PT; Doktorova M; Meijsen KF; Nieuwenhuijze NDA; Verkade HJ; Jonker JW; de Jonge HR; Bijvelds MJC
Cell Mol Gastroenterol Hepatol; 2020; 9(1):47-60. PubMed ID: 31470114
[TBL] [Abstract][Full Text] [Related]
12. An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers.
Al-Khaifi A; Rudling M; Angelin B
Gastroenterology; 2018 Oct; 155(4):1012-1016. PubMed ID: 29928896
[TBL] [Abstract][Full Text] [Related]
13. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation.
Degirolamo C; Modica S; Vacca M; Di Tullio G; Morgano A; D'Orazio A; Kannisto K; Parini P; Moschetta A
Hepatology; 2015 Jan; 61(1):161-70. PubMed ID: 24954587
[TBL] [Abstract][Full Text] [Related]
14. FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection.
Cao Y; Xiao Y; Zhou K; Yan J; Wang P; Yan W; Cai W
Am J Physiol Gastrointest Liver Physiol; 2019 Aug; 317(2):G108-G115. PubMed ID: 30920307
[TBL] [Abstract][Full Text] [Related]
15. Tissue-specific mechanisms of bile acid homeostasis and activation of FXR-FGF19 signaling in preterm and term neonatal pigs.
Vonderohe C; Guthrie G; Stoll B; Chacko S; Dawson H; Burrin DG
Am J Physiol Gastrointest Liver Physiol; 2022 Jan; 322(1):G117-G133. PubMed ID: 34851728
[TBL] [Abstract][Full Text] [Related]
16. FXR-FGF19 signaling in the gut-liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence.
Simbrunner B; Hofer BS; Schwabl P; Zinober K; Petrenko O; Fuchs C; Semmler G; Marculescu R; Mandorfer M; Datz C; Trauner M; Reiberger T
Hepatol Int; 2024 Jun; 18(3):929-942. PubMed ID: 38332428
[TBL] [Abstract][Full Text] [Related]
17. No Gut No Gain! Enteral Bile Acid Treatment Preserves Gut Growth but Not Parenteral Nutrition-Associated Liver Injury in a Novel Extensive Short Bowel Animal Model.
Villalona G; Price A; Blomenkamp K; Manithody C; Saxena S; Ratchford T; Westrich M; Kakarla V; Pochampally S; Phillips W; Heafner N; Korremla N; Greenspon J; Guzman MA; Kumar Jain A
JPEN J Parenter Enteral Nutr; 2018 Nov; 42(8):1238-1251. PubMed ID: 29701901
[TBL] [Abstract][Full Text] [Related]
18. Hepatic cholesterol accumulation ascribed to the activation of ileum Fxr-Fgf15 pathway inhibiting hepatic Cyp7a1 in high-fat diet-induced obesity rats.
Duan Y; Zhang F; Yuan W; Wei Y; Wei M; Zhou Y; Yang Y; Chang Y; Wu X
Life Sci; 2019 Sep; 232():116638. PubMed ID: 31288013
[TBL] [Abstract][Full Text] [Related]
19. FXR Primes the Liver for Intestinal FGF15 Signaling by Transient Induction of β-Klotho.
Fu T; Kim YC; Byun S; Kim DH; Seok S; Suino-Powell K; Xu HE; Kemper B; Kemper JK
Mol Endocrinol; 2016 Jan; 30(1):92-103. PubMed ID: 26505219
[TBL] [Abstract][Full Text] [Related]
20. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist.
Sayin SI; Wahlström A; Felin J; Jäntti S; Marschall HU; Bamberg K; Angelin B; Hyötyläinen T; Orešič M; Bäckhed F
Cell Metab; 2013 Feb; 17(2):225-35. PubMed ID: 23395169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
